NeurOptics’ Neurological Pupil index and automated pupillometry included in latest European guidelines for post-resuscitation care

The Neurological Pupil index (NPi) and automated NPi pupillometry globally emerging as important for use in patients following cardiac arrest NeurOptics NPi Pupillometer (Credit: Business Wire) NeurOptics’ Neurological Pupil index (NPi) and automated pupillometry are now included in the updated 2021 European Resuscitation Council (ERC) and European Society of Intensive Care Medicine (ESICM) Guidelines for post-resuscitation care as an objective measurement supporting neurological prognosis in patients following cardiac arrest. The ERC and ESICM guidelines outline the latest European post-resuscitation care science and treatment recommendations, based on the 2020 International Consensus on CPR and ECC Science with Treatment Recommendations (CoSTR), and are considered the gold standard of clinical recommendations in the practice of resuscitation science in Europe. The guidelines were last updated in 2015 and reflect alignment with the International Liaison Committee on Resuscitation (ILCOR) and associated member councils. NeurOptics’ NPi Pupillometry has emerged as an important technology that provides a quantitative measurement of pupil size and reactivity, expressed as the Neurological Pupil index (NPi). The NPi measurement is an objective assessment of the entire pupillary light reflex (PLR) that previous studies have demonstrated can be an early indicator of neurological injury in critically ill patients.1-3 NPi values range from 0 to 4.9, with scores under 3 considered abnormal, and are not significantly influenced by common ICU medications such as opioids, neuromuscular blocking agents (NMBA’s), and sedatives. The latest ERC-ESICM guidelines cite several recent clinical publications investigating the value of NPi in post-cardiac arrest patient management, noting the evidence demonstrated “…unlike s-PLR, NPi can predict unfavourable outcome with no false positives from 24 h or less to 72 h from ROSC. In one study this was because of the ability of the pupillometer to detect a response even when the pupil size was very small, presumably from sedation…” Automated assessment of pupillary reactivity, measured by the NPi, provides an objective measurement of pupil size and reactivity to help support the prognosis of poor neurological outcome in patients who remain comatose 72 hours after cardiac arrest. “The inclusion of automated pupillometry and the Neurological Pupil index (NPi) in the European guidelines reflects the growing body of evidence indicating quantitative NPi has a superior ability to predict unfavorable outcome after cardiac arrest compared to standard manual pupillary examination,” said Fabio Taccone, MD, PhD, Director of the Neuro-ICU at Erasme Hospital in Brussels, Belgium and co-author of the 2021 ERC and ESICM Guidelines for Post-Resuscitation Care. “The objectivity and reproducibility provided by NPi pupillometry, especially for patients in the ICU on a variety of medications, makes it the gold standard for pupillary assessment in outcome prediction of our critically ill patients.” The NeurOptics NPi Pupillometer eliminates the variability and subjectivity inherent in manual pupillary evaluation, providing a more accurate and reliable pupil size and reactivity measurement for patients with the potential for brain injury across a broad spectrum of conditions, including patients who have suffered cardiac arrest. Source: Company Press Release
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
-
Drugs
-
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.